rospedРоссийский педиатрический журнал имени М.Я. СтуденикинаM.Ya. Studenikin Russian Pediatric JournalФГАУ «НМИЦ здоровья детей» Минздрава России10.46563/1560-9561-2023-26-6-426-429ynzkgrrosped-382Research ArticleОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯORIGINAL INVESTIGATIONSЭффективность применения синбиотика в комплексной терапии острых кишечных инфекций у детейThe effectiveness of the use of synbiotics in the complex therapy of acute intestinal infections in childrenhttps://orcid.org/0000-0003-3248-5519СутовскаяДиана ВладимировнаSutovskayaDiana V.

Канд. мед. наук, врач-педиатр, ГБУЗ «Детская городская поликлиника № 1 г. Краснодар»; доцент каф. педиатрии № 2 ФГБОУ ВО «Кубанский государственный медицинский университет» Минздрава России

e-mail: dsutovskaya@bk.ru

MD, PhD, pediatrician, GBUZ "Children's City Polyclinic No. 1 Krasnodar" of the Ministry of Health of the Krasnodar Territory; Associate prof. of the Department of Pediatrics No. 2 of the Kuban State Medical University of the Ministry of Health of the Russian Federation

e-mail: dsutovskaya@bk.ru

dsutovskaya@bk.ruЛитвиновДаниил ИгоревичLitvinovDaniil I.

Студент лечебного факультета ФГБОУ ВО «Кубанский государственный медицинский университет» Минздрава России

e-mail: DaniilLitv2012@yandex.ru

DaniilLitv2012@yandex.ruГБУЗ «Детская городская поликлиника № 1 г. Краснодар» Минздрава Краснодарского края; ФГБОУ ВО «Кубанский государственный медицинский университет» Минздрава РоссииChildren’s Municipal Polyclinic No. 1; Kuban State Medical UniversityФГБОУ ВО «Кубанский государственный медицинский университет» Минздрава РоссииKuban State Medical University202306012024266426429Copyright © Сутовская Д.В., Литвинов Д.И., 20242024Сутовская Д.В., Литвинов Д.И.Sutovskaya D.V., Litvinov D.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rosped.ru/jour/article/view/382Введение

Введение. Острые кишечные инфекции (ОКИ) у детей имеют большое значение в структуре детской заболеваемости и смертности, что обусловливает необходимость поиска средств и методов их активного лечения для улучшения прогноза.

Цель работы

Цель работы: определить эффективность применения синбиотика в комплексной терапии ОКИ у детей на этапе амбулаторно-поликлинического звена.

Материалы и методы

Материалы и методы. Обследовано 50 детей 6–17 лет с ОКИ лёгкой или среднетяжёлой степени тяжести. Пациенты рандомизированы на основную группу (30 детей) и контрольную группу (20 детей), группы сопоставимы. Больные основной группы наряду с патогенетической терапией получали синбиотик — комбинацию пробиотика (Lacticaseibacillus paracasei DG I-1572 DSM 34154) и пребиотика (фруктоолигосахариды), а дети из контрольной группы — только патогенетическое и симптоматическое лечение. В динамике производилась оценка клинических симптомов: изменения температуры тела, частоты и характера стула, наличие и выраженность диспептических проявлений, тошноты, рвоты, болевого абдоминального синдрома.

Результаты

Результаты. Использование синбиотика в патогенетической терапии ОКИ у детей уменьшает сроки купирования клинических проявлений. При этом выраженность болевого абдоминального синдрома уменьшается значительно быстрее по сравнению с контролем. Аналогично нормализуются частота и характер стула при одновременном назначении синбиотика и патогенетической терапии. Использованный синбиотик имеет высокий профиль безопасности, побочные проявления не отмечены.

Заключение

Заключение. Синбиотик как комбинацию пробиотика и пребиотика целесообразно назначать детям с 1-го дня ОКИ вместе с патогенетической и симптоматической терапией для быстрого достижения клинического эффекта.

Участие авторов

Участие авторов:Сутовская Д.В. — концепция и дизайн исследования, редактирование;Сутовская Д.В., Литвинов Д.И. — сбор и обработка материала, написание текста, утверждение окончательного варианта статьи, ответственность за целостность всех частей статьи.

Финансирование

Финансирование. Исследование не имело финансовой поддержки.

Конфликт интересов

Конфликт интересов. Авторы заявляют об отсутствии конфликта интересов.

Поступила 02

Поступила 02.11.2023Принята к печати 28.11.2023Опубликована 27.12.2023

Relevance

Relevance. Acute intestinal infections in children retain a high value in the structure of child morbidity and mortality, which necessitates the search for means and methods for their active treatment and improvement of prognosis.

Aim

Aim: to determine the effectiveness of the use of synbiotics in the complex therapy of acute intestinal infections in children at the outpatient stage.

Materials and methods

Materials and methods. Fifty 6–17 years children with mild or moderate acute intestinal infections were examined. The patients were divided into the main group (30 children) and the control group (20 children), the groups were comparable. Patients from the main group, along with pathogenetic therapy, received a combination of Lacticaseibacillus paracasei DG I-1572 DSM 34154 (L. casei DG) and fructooligosaccharides (FOS), and children from the control group received only pathogenetic and symptomatic treatment. Clinical symptoms were evaluated over following up included temperature, frequency and, nature of stool, presence and severity of dyspeptic manifestations, nausea, frequency of vomiting, presence and severity of abdominal pain syndrome. Statistical data processing was carried out using statistical analysis Statistica v. 13.0 (StatSoft Inc., USA).

Results

Results. The combined use of L. casei DG and FOS in the pathogenetic therapy of acute intestinal infections reduces the time of relief of clinical manifestations. The severity of abdominal pain syndrome regresses significantly faster when using this synbiotic. Normalization of the frequency and nature of stool occurs significantly faster with the simultaneous appointment of pathogenetic therapy and the synbiotic. The combination of L. casei DG and FOS has demonstrated a high safety profile, side effects have not been reported.

Conclusion

Conclusion. It is advisable to prescribe the combination of L. casei DG and FOS from the first day of acute intestinal infections alongside with pathogenetic and symptomatic therapy to achieve a clinical effect more quickly.

Contribution

Contribution: Sutovskaya D.V. — concept and design of the study, editing; Sutovskaya D.V., Litvinov D.I. — collection and processing of material, writing the text, approval of the final version of the article, responsibility for the integrity of all parts of the article.

Acknowledgment

Acknowledgment. The study had no sponsorship.

Conflict of interest

Conflict of interest. The authors declare no conflict of interest.

Received

Received: November 02, 2023Accepted: November 28, 2023Published: December 27, 2023

острые кишечные инфекциидетипробиотиксинбиотикклиническое исследованиеacute intestinal infectionschildrenprobioticsymbioticclinical studyReferencesУсенко Д.В., Горелова Е.А. Острые кишечные инфекции вирусной этиологии у детей: возможности диагностики и терапии. Медицинский совет. 2017; (9): 86–92. https://doi.org/10.21518/2079-701X-2017-9-86-92 https://elibrary.ru/zcirjnUsenko D.V., Gorelova E.A. Acute intestinal infections of viral etiology in children: prospects for diagnosis and therapy. Meditsinskiy sovet. 2017; (9): 86–92. https://doi.org/10.21518/2079-701X-2017-9-86-92 https://elibrary.ru/zcirjn (in Russian)Xiong L., Li Y., Li J., Yang J., Shang L., He X., et al. Intestinal microbiota profiles in infants with acute gastroenteritis caused by rotavirus and norovirus infection: a prospective cohort study. Int. J. Infect. Dis. 2021; 111: 76–84. https://doi.org/10.1016/j.ijid.2021.08.024Xiong L., Li Y., Li J., Yang J., Shang L., He X., et al. Intestinal microbiota profiles in infants with acute gastroenteritis caused by rotavirus and norovirus infection: a prospective cohort study. Int. J. Infect. Dis. 2021; 111: 76–84. https://doi.org/10.1016/j.ijid.2021.08.024Sturgeon J.P., Njunge J.M., Bourke C.D., Gonzales G.B., Robertson R.C., Bwakura-Dangarembizi M., et al. Inflammation: the driver of poor outcomes among children with severe acute malnutrition? Nutr. Rev. 2023; 81(12): 1636–52. https://doi.org/10.1093/nutrit/nuad030Sturgeon J.P., Njunge J.M., Bourke C.D., Gonzales G.B., Robertson R.C., Bwakura-Dangarembizi M., et al. Inflammation: the driver of poor outcomes among children with severe acute malnutrition? Nutr. Rev. 2023; 81(12): 1636–52. https://doi.org/10.1093/nutrit/nuad030Marasco G., Cirota G.G., Rossini B., Lungaro L., Di Biase A.R., Colecchia A., et al. Probiotics, prebiotics and other dietary supplements for gut microbiota modulation in celiac disease patients. Nutrients. 2020; 12(9): 2674. https://doi.org/10.3390/nu12092674Marasco G., Cirota G.G., Rossini B., Lungaro L., Di Biase A.R., Colecchia A., et al. Probiotics, prebiotics and other dietary supplements for gut microbiota modulation in celiac disease patients. Nutrients. 2020; 12(9): 2674. https://doi.org/10.3390/nu12092674Martyniak A., Medyńska-Przęczek A., Wędrychowicz A., Skoczeń S., Tomasik P.J. Prebiotics, probiotics, synbiotics, paraprobiotics and postbiotic compounds in IBD. Biomolecules. 2021; 11(12): 1903. https://doi.org/10.3390/biom11121903Martyniak A., Medyńska-Przęczek A., Wędrychowicz A., Skoczeń S., Tomasik P.J. Prebiotics, probiotics, synbiotics, paraprobiotics and postbiotic compounds in IBD. Biomolecules. 2021; 11(12): 1903. https://doi.org/10.3390/biom11121903Plaza-Díaz J., Ruiz-Ojeda F.J., Gil-Campos M., Gil A. Immune-mediated mechanisms of action of probiotics and synbiotics in treating pediatric intestinal diseases. Nutrients. 2018; 10(1): 42. https://doi.org/10.3390/nu10010042Plaza-Díaz J., Ruiz-Ojeda F.J., Gil-Campos M., Gil A. Immune-mediated mechanisms of action of probiotics and synbiotics in treating pediatric intestinal diseases. Nutrients. 2018; 10(1): 42. https://doi.org/10.3390/nu10010042Morgan R.L., Preidis G.A., Kashyap P.C., Weizman A.V., Sadeghirad B. Probiotics reduce mortality and morbidity in preterm, low-birth-weight infants: a systematic review and network meta-analysis of randomized trials. Gastroenterology. 2020; 159(2): 467–80. https://doi.org/10.1053/j.gastro.2020.05.096Morgan R.L., Preidis G.A., Kashyap P.C., Weizman A.V., Sadeghirad B. Probiotics reduce mortality and morbidity in preterm, low-birth-weight infants: a systematic review and network meta-analysis of randomized trials. Gastroenterology. 2020; 159(2): 467–80. https://doi.org/10.1053/j.gastro.2020.05.096Nolan L.S., Rimer J.M., Good M. The role of human milk oligosaccharides and probiotics on the neonatal microbiome and risk of necrotizing enterocolitis: a narrative review. Nutrients. 2020; 12(10): 3052. https://doi.org/10.3390/nu12103052Nolan L.S., Rimer J.M., Good M. The role of human milk oligosaccharides and probiotics on the neonatal microbiome and risk of necrotizing enterocolitis: a narrative review. Nutrients. 2020; 12(10): 3052. https://doi.org/10.3390/nu12103052Dargenio V.N., Castellaneta S., Panico S., Papagni M.E., Dargenio C., Schettini F., et al. Probiotics and gastrointestinal diseases. Minerva Pediatr. (Torino). 2022; 74(6): 703–23. https://doi.org/10.23736/S2724-5276.22.07031-8Dargenio V.N., Castellaneta S., Panico S., Papagni M.E., Dargenio C., Schettini F., et al. Probiotics and gastrointestinal diseases. Minerva Pediatr. (Torino). 2022; 74(6): 703–23. https://doi.org/10.23736/S2724-5276.22.07031-8Horne R.G., Freedman S.B., Johnson-Henry K.C., Pang X.L., Lee B.E., Farion K.J., et al. Intestinal microbial composition of children in a randomized controlled trial of probiotics to treat acute gastroenteritis. Front. Cell Infect. Microbiol. 2022; 12: 883163. https://doi.org/10.3389/fcimb.2022.883163Horne R.G., Freedman S.B., Johnson-Henry K.C., Pang X.L., Lee B.E., Farion K.J., et al. Intestinal microbial composition of children in a randomized controlled trial of probiotics to treat acute gastroenteritis. Front. Cell Infect. Microbiol. 2022; 12: 883163. https://doi.org/10.3389/fcimb.2022.883163Radicioni M., Koirala R., Fiore W., Leuratti C., Guglielmetti S., Arioli S. Survival of L. casei DG® (Lactobacillus paracasei CNCMI1572) in the gastrointestinal tract of a healthy paediatric population. Eur. J. Nutr. 2019; 58(8): 3161–70. https://doi.org/10.1007/s00394-018-1860-5Radicioni M., Koirala R., Fiore W., Leuratti C., Guglielmetti S., Arioli S. Survival of L. casei DG® (Lactobacillus paracasei CNCMI1572) in the gastrointestinal tract of a healthy paediatric population. Eur. J. Nutr. 2019; 58(8): 3161–70. https://doi.org/10.1007/s00394-018-1860-5Bretto E., D’Amico F., Fiore W., Tursi A., Danese S. Lactobacillus paracasei CNCM I 1572: A promising candidate for management of colonic diverticular disease. J. Clin. Med. 2022; 11(7): 1916. https://doi.org/10.3390/jcm11071916Bretto E., D’Amico F., Fiore W., Tursi A., Danese S. Lactobacillus paracasei CNCM I 1572: A promising candidate for management of colonic diverticular disease. J. Clin. Med. 2022; 11(7): 1916. https://doi.org/10.3390/jcm11071916Szopa K., Szajnar K., Pawlos M., Znamirowska-Piotrowska A. Probiotic fermented goat’s and sheep’s milk: effect of type and dose of collagen on survival of four strains of probiotic bacteria during simulated in vitro digestion conditions. Nutrients. 2023; 15(14): 3241. https://doi.org/10.3390/nu15143241Szopa K., Szajnar K., Pawlos M., Znamirowska-Piotrowska A. Probiotic fermented goat’s and sheep’s milk: effect of type and dose of collagen on survival of four strains of probiotic bacteria during simulated in vitro digestion conditions. Nutrients. 2023; 15(14): 3241. https://doi.org/10.3390/nu15143241Hyoung A., Kim J., Hogarty M.P., Harris V.C., Baldridge M.T. The complex interactions between rotavirus and the gut microbiota. Front. Cell. Infect. Microbiol. 2021: 10: 586751. https://doi.org/10.3389/fcimb.2020.586751.89Hyoung A., Kim J., Hogarty M.P., Harris V.C., Baldridge M.T. The complex interactions between rotavirus and the gut microbiota. Front. Cell. Infect. Microbiol. 2021: 10: 586751. https://doi.org/10.3389/fcimb.2020.586751.89Liu Y., Tran D.Q., Rhoads J.M. Probiotics in disease prevention and treatment. J. Clin. Pharmacol. 2018; 58(Suppl. 10): 164–79. https://doi.org/10.1002/jcph.1121Liu Y., Tran D.Q., Rhoads J.M. Probiotics in disease prevention and treatment. J. Clin. Pharmacol. 2018; 58(Suppl. 10): 164–79. https://doi.org/10.1002/jcph.1121Cukrowska B., Bierła J.B., Zakrzewska M., Klukowski M., Maciorkowska E. The Relationship between the infant gut microbiota and allergy. The role of Bifidobacterium breve and prebiotic oligosaccharides in the activation of anti-allergic mechanisms in early life. Nutrients. 2020; 12(4): 946. https://doi.org/10.3390/nu12040946Cukrowska B., Bierła J.B., Zakrzewska M., Klukowski M., Maciorkowska E. The Relationship between the infant gut microbiota and allergy. The role of Bifidobacterium breve and prebiotic oligosaccharides in the activation of anti-allergic mechanisms in early life. Nutrients. 2020; 12(4): 946. https://doi.org/10.3390/nu12040946Kaufmann B., Seyfried N., Hartmann D., Hartmann P. Probiotics, prebiotics, and synbiotics in nonalcoholic fatty liver disease and alcohol-associated liver disease. Am. J. Physiol. Gastrointest. Liver. Physiol. 2023; 325(1): 42–61. https://doi.org/10.1152/ajpgi.00017.2023Kaufmann B., Seyfried N., Hartmann D., Hartmann P. Probiotics, prebiotics, and synbiotics in nonalcoholic fatty liver disease and alcohol-associated liver disease. Am. J. Physiol. Gastrointest. Liver. Physiol. 2023; 325(1): 42–61. https://doi.org/10.1152/ajpgi.00017.2023Wala S.J., Ragan M.V., Sajankila N., Volpe S.G., Purayil N., Dumbauld Z., et al. Probiotics and novel probiotic delivery systems. Semin. Pediatr. Surg. 2023; 32(3): 151307. https://doi.org/10.1016/j.sempedsurg.2023.151307.10Wala S.J., Ragan M.V., Sajankila N., Volpe S.G., Purayil N., Dumbauld Z., et al. Probiotics and novel probiotic delivery systems. Semin. Pediatr. Surg. 2023; 32(3): 151307. https://doi.org/10.1016/j.sempedsurg.2023.151307.10Akutko K., Stawarski A. Probiotics, prebiotics and synbiotics in inflammatory bowel diseases. J. Clin. Med. 2021; 10(11): 2466. https://doi.org/10.3390/jcm10112466Akutko K., Stawarski A. Probiotics, prebiotics and synbiotics in inflammatory bowel diseases. J. Clin. Med. 2021; 10(11): 2466. https://doi.org/10.3390/jcm10112466Wallace C., Gordon M., Sinopoulou V., Akobeng A.K. Probiotics for management of functional abdominal pain disorders in children. Cochrane Database Syst. Rev. 2023; 2(2): CD012849. https://doi.org/10.1002/14651858.CD012849.pub2Wallace C., Gordon M., Sinopoulou V., Akobeng A.K. Probiotics for management of functional abdominal pain disorders in children. Cochrane Database Syst. Rev. 2023; 2(2): CD012849. https://doi.org/10.1002/14651858.CD012849.pub2

The authors declare that there are no conflicts of interest present.